Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-20-003852
Filing Date
2020-11-12
Accepted
2020-11-12 16:01:57
Documents
37
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q cns_10q-093020.htm 10-Q 302449
2 CERTIFICATION cns_10q-ex3101.htm EX-31.1 7163
3 CERTIFICATION cns_10q-ex3102.htm EX-31.2 7290
4 CERTIFICATION cns_10q-ex3201.htm EX-32.1 3139
5 CERTIFICATION cns_10q-ex3202.htm EX-32.2 3274
  Complete submission text file 0001683168-20-003852.txt   1806182

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE cnsp-20200930.xml EX-101.INS 268726
7 XBRL SCHEMA FILE cnsp-20200930.xsd EX-101.SCH 20007
8 XBRL CALCULATION FILE cnsp-20200930_cal.xml EX-101.CAL 28266
9 XBRL DEFINITION FILE cnsp-20200930_def.xml EX-101.DEF 86897
10 XBRL LABEL FILE cnsp-20200930_lab.xml EX-101.LAB 175987
11 XBRL PRESENTATION FILE cnsp-20200930_pre.xml EX-101.PRE 139792
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185 X701
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39126 | Film No.: 201306506
SIC: 2834 Pharmaceutical Preparations